Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma

Published:2012 Issue:2 Volume:47 Page:119
ISSN:1738-7949
Container-title:The Korean Journal of Hematology
language:en
Short-container-title:Korean J Hematol

Author:

Jo Jae-Cheol¹,Yoon Dok Hyun¹,Kim Shin¹,Park Jung Sun¹,Park Chan-Sik²,Huh Jooryung²,Lee Sang-Wook³,Ryu Jin-Sook⁴,Suh Cheolwon¹

Affiliation:

1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

3. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

4. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/kjh.2012.47.2.119

Reference30 articles.

1. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

2. High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial

3. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

4. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis

5. Autologous Transplantation for Diffuse Aggressive Non-Hodgkin’s Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal-hämatopoetische Stammzellachse: Anwendungen für die Induktion von hämatopoetischem Chimärismus und Therapien für bösartige Erkrankungen;Stammzellen;2023

2. Mesenchymal–Hematopoietic Stem Cell Axis: Applications for Induction of Hematopoietic Chimerism and Therapies for Malignancies;Stem Cells;2021

3. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas;Annals of Hematology;2020-11-17

4. Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL);Bone Marrow Transplantation;2020-04-17

5. Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma;International Journal of Hematologic Oncology;2018-03-01